top of page

®

Foveal LLP Independent Investment Research Foveal Research

Independent Investment Research

Focus Research

ADC: AZN Dato overall survival misses underscores our long held concerns for ADC's in 1L Lung

ADC: AZN Dato overall survival misses underscores our long held concerns for ADC's in 1L Lung

WCLC: Hold you HARMONis: Keytruda safe from Summit

WCLC: Hold you HARMONis: Keytruda safe from Summit

ADCs @ ASCO: concerns over Dato-DXd in 1L Lung; GILD 2L OS as bad as AZN; SKB high ORR in unusual trial

ADCs @ ASCO: concerns over Dato-DXd in 1L Lung; GILD 2L OS as bad as AZN; SKB high ORR in unusual trial

MRNA/MRK: ASCO cancer vaccine data does not address pre-treatment imbalances that may be driving result

MRNA/MRK: ASCO cancer vaccine data does not address pre-treatment imbalances that may be driving result

ROG/SRPT: Duchenne EMBARK likely enought to lessen age restrictions

ROG/SRPT: Duchenne EMBARK likely enought to lessen age restrictions

AZN/ROG: Roche/AZN: SERDs restrict or fail

AZN/ROG: Roche/AZN: SERDs restrict or fail

Recent Research

Still no light from TIGIT trials at ASCO23

May 28, 2023

Still no light from TIGIT trials at ASCO23

While ASCO 2023 does not offer much in updates for the three current lead contenders for anti-TIGIT combinations in non-small cell lung canc

ADC: AZN Dato overall survival misses underscores our long held concerns for ADC's in 1L Lung

ADC: AZN Dato overall survival misses underscores our long held concerns for ADC's in 1L Lung

Oct 3

WCLC: Hold you HARMONis: Keytruda safe from Summit

Sep 22

ADCs @ ASCO: concerns over Dato-DXd in 1L Lung; GILD 2L OS as bad as AZN; SKB high ORR in unusual trial

ADCs @ ASCO: concerns over Dato-DXd in 1L Lung; GILD 2L OS as bad as AZN; SKB high ORR in unusual trial

Jul 1

MRNA/MRK: ASCO cancer vaccine data does not address pre-treatment imbalances that may be driving result

Jun 18

ROG/SRPT: Duchenne EMBARK likely enought to lessen age restrictions

May 29

AZN/ROG: Roche/AZN: SERDs restrict or fail

Apr 23

CYTK/BMY: aficamten approvable, but may not be better than BMY rival Camzyos

CYTK/BMY: aficamten approvable, but may not be better than BMY rival Camzyos

Feb 29

MRK: One big hit amongst smaller approvable assets

MRK: One big hit amongst smaller approvable assets

Feb 5

BMY/JNJ/BAYN: Bayer AF failure does not reduce chances for Factor XI in stroke

Nov 20, 2023

AZN/GILD/Daiichi: ADC's face stiff hurdles in 1st line lung cancer

AZN/GILD/Daiichi: ADC's face stiff hurdles in 1st line lung cancer

Oct 31, 2023

Archive

Search By Tags

Follow Us

Bloomberg: FOVL <go>

ThomsonReuters

FactSet

Captial IQ

bottom of page